Complete Program

PMC19 — COMPLETE PROGRAM




CONFERENCES

Lisbon 8 Novembro
8.30
Reception / Check-In / Networking
9.15
Opening Session

Carla Dias — Portuguese Observatory of Medical Cannabis President

The challenges of Medicinal Cannabis

09:30
Cristina Sanchez — Introduction to the Endocannabinoid System
Cristina Sanchez — Introduction to the Endocannabinoid System

The endocannabinoid system has a tremendous potential as a therapeutic target for a wide variety of ailments and symptoms. In this presentation, the molecular explanation for this potential will be provided by introducing the constituents of this system, its mode of action and the physiological functions it controls.

10:15
Adi Aran — Cannabinoid treatment and endocannabinoid system in Autism Spectrum Disorder (ASD)
Adi Aran — Cannabinoid treatment and endocannabinoid system in Autism Spectrum Disorder (ASD)

Clinical use of various cannabis strains in children with ASD is rapidly expanding but published evidence is sparse. This presentation will discuss preclinical studies that suggest involvement of the endocannabinoid system in the pathogenesis of autism spectrum disorder (ASD) as well as past, present and future clinical studies.

11:00
Coffee Break & Networking
Coffee Break & Networking
11:30
Mara Gordon — How to begin a cannabis treatment protocol and choose the right medication
Mara Gordon — How to begin a cannabis treatment protocol and choose the right medication

With cannabis moving into more mainstream acceptance, emergency rooms are seeing an upsurge in visits from people trying different cannabis products without any idea how to properly consume. We will learn how to demystify product labels, and how to consume responsibly. Nothing is a bigger deterrent to cannabis adoption than a trip to the ER.

12:15
Janosch Kratz — Cannabinoids in chronic pain - How to break a vicious cycle
Janosch Kratz — Cannabinoids in chronic pain - How to break a vicious cycle

The use of Cannabis in pain is probably the oldest existing condition for the use of Cannabinoids in medicine. As a result of this subject appearing more often in publications; patient statements; newspaper articles etc. people commonly think that Cannabinoids are just another medical Drug to add to the analgesic chart together with other well-known drugs like NSAID’s or Opioids. Working in daily practice with Cannabinoids we learn that there are more medical benefits besides the simple reduction of pain intensity. This presentation explains the multiple ways patients can benefit from cannabis in chronic pain conditions and lightens up limitations of many studies regarding this subject.

13:00
LUNCH (Not Included)
14:30
Philippe Lucas — The Exit Drug: cannabis in the Treatment of Pain, Mental Health and Addiction
Philippe Lucas — The Exit Drug: cannabis in the Treatment of Pain, Mental Health and Addiction

A brief overview of a few clinical and observational studies taking place in Canada, Australia and the US, with a focus on the patient patterns of use, the use of medical cannabis in the treatment of pain and mental health, and associated reductions in the use of prescription opioids and other substances.

15:15
Manuel Guzmán — Cannabinoids and neuroprotection
Manuel Guzmán — Cannabinoids and neuroprotection

The current state of the research on the therapeutic effects of cannabinoids in neurodegenerative diseases will be summarized in this presentation. The preclinical and clinical evidence suggesting the use of cannabinoids in this field will be discussed.

16:00
Coffee Break & Networking
Coffee Break & Networking
16:30
VIDEOCONFERENCE — Franjo Grotenhermen / Ethan Russo
VIDEOCONFERENCE — Franjo Grotenhermen / Ethan Russo

Ethan Russo: Cannabis has been utilized from time immemorial to treat grief, pain, sleep disorders and even mental illness. The discovery of the endocannabinoid system and its critical role in neurotransmission and homeostasis of the limbic system and other brain areas provide a rationale for utilization of properly formulated cannabis-based medicines in treatment of myriad psychiatric conditions. Historical claims will be presented along with basic science and clinical trial data to assess the current future role of cannabis psychopharmacology with respect to issues of impairment, depression, insomnia, PTSD, schizophrenia, anxiety and addiction. Appropriate formulations for cannabis chemovars will be suggested.

Franjo Grotenhermen: Cannabis, THC and CBD may interact with other medicinal drugs. Some of these interactions may be of medicinal value, for example increase of pain reduction by THC and opioids, while others may be unwanted, such as uncontrolled influence on blood concentrations of other antiepileptic drugs.
Interactions of THC and CBD may be divided into pharmacokinetic interactions (usually based on degradation issues) and pharmacodynamic interactions (usually based on the effects of CBD and THC on the one hand and other medications on the other hand.”

17:15
Gregor Zorn — 10 things you should know before using medical cannabis
Gregor Zorn — 10 things you should know before using medical cannabis

A beginner’s guide on the use of medical cannabis, that will answer the main questions patients usually have and comprehensively explain the most important aspects of using medical cannabis. Some of the topics that will be covered; how to correctly and efficiently use medical cannabis, how to start dosing, the differences between the methods of administration, reducing and preventing unwanted side effects, what to look for in cannabis products, debunking cannabis myths and misconceptions.

18:00
Sandra Carrillo — Cannabinoids in Epilepsy: Scientific Evidence
Sandra Carrillo — Cannabinoids in Epilepsy: Scientific Evidence

This presentation seeks to review the pre-clinical data suggesting a therapeutic potential of cannabinoids for the treatment of epilepsy.

I will also to review the clinical data of cannabinoids as a treatment for epilepsy. The objective is to explore the understanding and discussion of the benefits and adverse effects of cannabinoids in the treatment of this pathology.

Open to the general public.

18:45
Closing Session

Speaker to be defined

PORTO 22 Novembro
8.30
Reception / Check-In / Networking
9.15
Opening Session

Carla Dias — Portuguese Observatory of Medical Cannabis President

The challenges of Medicinal Cannabis

9:30
Arno Hazekamp — The biochemistry of medicinal cannabis explained
Arno Hazekamp — The biochemistry of medicinal cannabis explained

If cannabis is considered a medicine, it means there must be bioactive ingredients present in the plant. Everyone has heard about cannabinoids and terpenes, but where do they come from, and what is their behaviour in different administration forms? Is the entourage effect a real thing, and how does it work? Are CBD products always safe, or should we be carefull when we consume these products? What makes cannabis varieties different, and how do you analyze all these active components in a lab? The answers are all related to the biochemistry of cannabis. This presentation will follow the trail of active compounds from flower to product to patient. Shrink yourself to the size of a molecule and join this biochemistry trip.

10:15
Cristina Sanchez — Cannabis and Cancer: Scientific Answers to Frequently Asked Questions
Cristina Sanchez — Cannabis and Cancer: Scientific Answers to Frequently Asked Questions

In this presentation, the preclinical data supporting the use of cannabinoids as antitumor agents will be discussed. In addition, answers to the most frequenltly asked questions (what kind of canabis should be used? What route of administration? Can cannabis be combined with other treatments?) will be answered from a strictly scientific perspective.

11:00
Coffee Break & Networking
Coffee Break & Networking
11:30
Sandra Carrilho — Cannabinoids in Epilepsy: Scientific Evidence
Sandra Carrilho — Cannabinoids in Epilepsy: Scientific Evidence

This presentation seeks to review the pre-clinical data suggesting a therapeutic potential of cannabinoids for the treatment of epilepsy.

I will also to review the clinical data of cannabinoids as a treatment for epilepsy. The objective is to explore the understanding and discussion of the benefits and adverse effects of cannabinoids in the treatment of this pathology.

Open to the general public.

12:15
José Tempero — Cannabinoid-based medicine: How to capture evidence to demonstrate its added clinical value?
José Tempero — Cannabinoid-based medicine: How to capture evidence to demonstrate its added clinical value?

This communication will give a brief summary of what is meant by the benefit-risk balance associated with classical medicines, duly registered with the various drug agencies, and what parallelism can be found in the available products containing cannabis or cannabis derivatives for therapeutic purposes. Quality assurance and reproducibility themes will be reflected as well as ways to capture the clinical evidence of cannabis medicine and its added therapeutic value.

13:00
LUNCH (Not Included)
14:30
David (Dedi) Meiri
David (Dedi) Meiri

From Pre-Clinical to Clinical, the Unique Situation of Cannabis

15:15
Janosch Kratz — Cannabinoids in chronic pain - How to break a vicious cycle
Janosch Kratz — Cannabinoids in chronic pain - How to break a vicious cycle

The use of Cannabis in pain is probably the oldest existing condition for the use of Cannabinoids in medicine. As a result of this subject appearing more often in publications; patient statements; newspaper articles etc. people commonly think that Cannabinoids are just another medical Drug to add to the analgesic chart together with other well-known drugs like NSAID’s or Opioids. Working in daily practice with Cannabinoids we learn that there are more medical benefits besides the simple reduction of pain intensity. This presentation explains the multiple ways patients can benefit from cannabis in chronic pain conditions and lightens up limitations of many studies regarding this subject.

16:00
Coffee Break & Networking
Coffee Break & Networking
16:30
Paulo Freitas Tavares — Canabis Past and Present in Oncology
Paulo Freitas Tavares — Canabis Past and Present in Oncology

How the utility of cannabis in HUC was discovered and how its use has evolved.
Side effects of cytostatic and analgesic medication and the interest of association with cannabis derivatives.

Patient strategies while there is no affordable drug in pharmacies.
Toxicity and the search for the optimal dose in an unregulated black market. Actual stories of more or less consented use.

The uselessness of hemp oils in oncology.

17:15
João Taborda da Gama — The legal framework of medical cannabis
João Taborda da Gama — The legal framework of medical cannabis

A description of the laws applicable to medical cannabis and the main challenges and open questions today.

18:00
Bruno Maia — Cannabis in neurological diseases: what we know (and what we don't know)
Bruno Maia — Cannabis in neurological diseases: what we know (and what we don't know)

Following the publication of clinical trials demonstrating the effectiveness of CBD oil in certain childhood epileptic syndromes, many questions remained unanswered. Can cannabis be used for adult epilepsy? And what is the role of cannabis in migraine? In Parkinson’s disease? In Multiple Sclerosis?

18:45
Closing Session

Speaker to be defined



WORKSHOPS

Lisbon 9 Novembro
8.30
Reception / Check-In
9:00
Adi Aran — Practical aspects of cannabinoid treatment in Autism
Adi Aran — Practical aspects of cannabinoid treatment in Autism

This workshop will discuss the clinical aspects of cannabinoid treatment in ASD: Target populations within the autism spectrum; When can we try? Which treatments should be considered? Is there really an entourage effect in ASD? Dose and administration; Concomitant use of medications; Tolerance; Adverse events; and Safety.

10:00
Cristina Sanchez — Antitumoral activity of cannabinoids in breast cancer
Cristina Sanchez — Antitumoral activity of cannabinoids in breast cancer

The current state of the research on the potential therapeutic effects of cannabinoids in breast cancer will be summarized in this presentation. The preclinical evidence supporting the antitumoral activity of cannabinoids in breast cancer will be presented and discussed.

11:00
Coffee Break & Networking
Coffee Break & Networking
11:30
Manuel Guzmán — Antitumoral activity of cannabinoids in glioblastoma
Manuel Guzmán — Antitumoral activity of cannabinoids in glioblastoma

“The current state of the research on the potential therapeutic effects of cannabinoids in glioblastoma will be summarized in this presentation. The preclinical evidence supporting the antitumoral activity of cannabinoids in glioblastoma will be presented and discussed. “

12:30
LUNCH (Not Included)
14:00
Janosch Kratz — Cannabinoids in daily live as a physician – A practical approach
Janosch Kratz — Cannabinoids in daily live as a physician – A practical approach

Worldwide we are observing a constantly growing number of countries legalizing Cannabinoids for medical purposes – more and more doctors and patients are now aware of and interested in the matter of cannabis and its medical use. Due to the complexity of the subject, the lack of medical books and guidelines and its absence in the Curriculum of most medical faculties around the world it seems nearly impossible to find solid information. Especially for beginners it is a huge burden to find valid, high quality, science-based articles in the jungle of information we get through the many pages in the World Wide Web. This leads to misunderstanding, stigmatization and confusion regarding all the aspects of this subject. This presentation aims to provide solid, science based and practical orientated information regarding the use of Cannabinoids in our daily work as a Doctor.

15:00
Mara Gordon — Diagnosis Breast Cancer: Now what?
Mara Gordon — Diagnosis Breast Cancer: Now what?

Receiving a cancer diagnosis may be the most frightening thing to occur in an individual’s life. With all the hype around cannabis and cancer, how is someone to know what to use and how to use it. We will look at the various types of cannabis products available, and delve into the bioavailability of various methods of ingestion..

16:00
Coffee Break & Networking
Coffee Break & Networking
16:30
Gregor Zorn — Medical cannabis: more than THC and CBD
Gregor Zorn — Medical cannabis: more than THC and CBD

THC and CBD are the main phytocannabinoids that are used in cannabinoid therapy and have shown great potential in the treatment of many medical conditions. While the spotlight is on these two cannabinoids, this plant has many other compounds, that have therapeutic value.
In this presentation we will talk about the less known constituents, their effects and how they could be used therapeutically in the near future. We will also mention other simple but effective methods, of enhancing the effectiveness of cannabinoid therapy.

17:30
Philippe Lucas — Medical cannabis patient patterns of use and treatment for pain, mental health and addiction: Results from large Canadian Observational Studies
Philippe Lucas — Medical cannabis patient patterns of use and treatment for pain, mental health and addiction: Results from large Canadian Observational Studies

This presentation will provide detailed data on patient patterns of use, the use of medical cannabis in the treatment of pain and mental health, and associated reductions in the use of prescription opioids and other substances. It will also explore age-related differences in cannabis use, with a focus on the shifts from the inhalation of THC to the ingestion of CBD in older populations.

PORTO 23 Novembro
8.30
Reception / Check-In
9.00
David (Dedi) Meiri
David (Dedi) Meiri
10:00
Arno Hazekamp — The biochemistry of medicinal cannabis explained
Arno Hazekamp — The biochemistry of medicinal cannabis explained

If cannabis is considered a medicine, it means there must be bioactive ingredients present in the plant. Everyone has heard about cannabinoids and terpenes, but where do they come from, and what is their behaviour in different administration forms? Is the entourage effect a real thing, and how does it work? Are CBD products always safe, or should we be carefull when we consume these products? What makes cannabis varieties different, and how do you analyze all these active components in a lab? The answers are all related to the biochemistry of cannabis. This presentation will follow the trail of active compounds from flower to product to patient. Shrink yourself to the size of a molecule and join this biochemistry trip.

11:00
Coffee Break & Networking
11:30
Cristina Sanchez — Introduction to the endocannabinoid system
Cristina Sanchez — Introduction to the endocannabinoid system

The endocannabinoid system has a tremendous potential as a therapeutic target for a wide variety of ailments and symptoms. In this presentation, the molecular explanation for this potential will be provided by introducing the constituents of this system, its mode of action and the physiological functions it controls.

12:30
LUNCH (Not Included)
14:00
Paulo Freitas Tavares — Cannabis Present and Future in Oncology
Paulo Freitas Tavares — Cannabis Present and Future in Oncology

The primary and secondary objective of clinical research.
The need for the creation of research centers focused on hospitals.
What we know and what remains to be known about the effects of cannabis on oncology. The need for research that should already be underway in all cancer patients. The need for research that should already be underway in all cancer patients.
The myth of “clinical trials” and why they are not suitable for cannabis.
The unknown cannabinoids and the surprising and unexpected effects. How to accelerate the translation of laboratory findings into clinical practice.

15:00
Bruno Maia — Cannabis in neurological diseases: what we know (and what we don't know)
Bruno Maia — Cannabis in neurological diseases: what we know (and what we don't know)

Following the publication of clinical trials demonstrating the efficacy of CBD oil in certain childhood epileptic syndromes, many questions remained unanswered. Can cannabis be used for adult epilepsy? And what is the role of cannabis in migraine? In Parkinson’s disease? In Multiple Sclerosis?

16:00
Coffee Break & Networking
Coffee Break & Networking
16:30
Sandra Carrillo — Cannabinoids in Epilepsy: Scientific Evidence.
Sandra Carrillo — Cannabinoids in Epilepsy: Scientific Evidence.

This presentation seeks to review the pre-clinical data suggesting a therapeutic potential of cannabinoids for the treatment of epilepsy. I will also to review the clinical data of cannabinoids as a treatment for epilepsy. The objective is to explore the understanding and discussion of the benefits and adverse effects of cannabinoids in the treatment of this pathology. This session is targeting Health Care Professionals, so content will be delivered at a more rigorous level of analysis, than for a general audience. Not recommended for non health care professionals.

17:30
Janosch Kratz — Cannabinoids in daily live as a physician – A practical approach
Janosch Kratz — Cannabinoids in daily live as a physician – A practical approach

Worldwide we are observing a constantly growing number of countries legalizing Cannabinoids for medical purposes – more and more doctors and patients are now aware of and interested in the matter of cannabis and its medical use. Due to the complexity of the subject, the lack of medical books and guidelines and its absence in the Curriculum of most medical faculties around the world it seems nearly impossible to find solid information. Especially for beginners it is a huge burden to find valid, high quality, science-based articles in the jungle of information we get through the many pages in the World Wide Web. This leads to misunderstanding, stigmatization and confusion regarding all the aspects of this subject. This presentation aims to provide solid, science based and practical orientated information regarding the use of Cannabinoids in our daily work as a Doctor.

18:30
Closing Session


PARALLEL SESSIONS

Lisboa 9 Novembro
9:00
Reception / Check-In / Networking
9:30
Michael Miller - A Survivors Story

A Wall Streeter’s cannabis Conversion. For 25 years Michael Miller took opiates to get through the pain of 3 nearly fatal accidents. He was never informed of alternatives by the US healthcare system. 5 years ago at the age of 54 he was introduced to cannabis as a medicine for the first time. This is his story …

10:00
Steven George — Medical cannabis Prohibition: An Untold Story
Steven George — Medical cannabis Prohibition: An Untold Story

A brief overview of the historical uses of medical cannabis and the economic production of cannabis long before it was prohibited in the United States, and eventually the rest of the world. We’ll take a journey through time to understand why the cannabis plant was prohibited in the early 1900’s, and why its re-introduction now poses unnecessary challenges for patients in need.

10:30
Bruno Maia — Cannabis in Neurological diseases: what we know (and what we don't know)
Bruno Maia — Cannabis in Neurological diseases: what we know (and what we don't know)

Following the publication of clinical trials demonstrating the efficacy of CBD oil in certain childhood epileptic syndromes, many questions remained unanswered. Can cannabis be used for adult epilepsy? And what is the role of cannabis in migraine? In Parkinson’s disease? In Multiple Sclerosis?

11:00
Coffee Break & Networking
Coffee Break & Networking
11:30
João Carvalho — History and Cultivation of Hemp in Portugal

Chronological journey on a secular relationship of Portugal with hemp. One presentation offers a trace from the Middle Ages through the Modern Age to contemporary times, with particular relevance to the first half of the twentieth century. Hemp was (as in the rest of the world) a major source of raw material for major machine manufacturers and manufacturers until the emergence of the petrochemical industry, yet it remains absent from textbooks, and belittled by traditional historiography.

12:30
Francisco Divo — Cannabis & Sports: ``The Perfect Match
Francisco Divo — Cannabis & Sports: ``The Perfect Match

Recently, with the legalization of cannabis in many countries worldwide, Cannabidiol (CBD), one of the main compounds of the plant, has been accepted for competitive use by the World Anti-doping Agency (WADA). This has allowed new clinical studies of cannabis to begin to be considered as a sports supplement as well as being a natural alternative for those athletes who frequently use anti-inflammatory medications and even opiates to relieve pain and inflammation after strenuous training or competition.

The fundamental pillars of an athlete are: Nutrition training and recovery. Cannabis and more specifically Cannabidiol (CBD) exerting effects on the CB1 and CB2 receptors of the endocannabinoid system contributes positively to improving these 3 essential aspects for the optimal performance of athletes. This phenomenon is well known to many athletes who have empirically been using cannabis for many years, many of them being publicly discredited and even expelled from professional skills and teams due to social stigmas and lack of information on the subject.

13:00
LUNCH ( Not Included)
LUNCH ( Not Included)
14:30
Sandra Carrillo — Cannabis, an ancient plant: redefining the future of medicine.
Sandra Carrillo — Cannabis, an ancient plant: redefining the future of medicine.
15:00
Mauro Lins — The use of CBD in the management of severe aggressive behavior in Autism Spectrum Disorders
Mauro Lins — The use of CBD in the management of severe aggressive behavior in Autism Spectrum Disorders

Dr. Lins will describe his successful experience with the use of CBD for autistic individuals who present with severe behavioral issues, including irritability and aggressiveness, unresponsive to usual psychiatric medications. Existing local legal barriers will also be addressed

15:30
João Taborda da Gama — Cannabis Regulations — The Regulatory Maze of CBD and non-THC cannabis
João Taborda da Gama — Cannabis Regulations — The Regulatory Maze of CBD and non-THC cannabis

A guided journey through one of the hardest regulatory issues today in the cannabis world. We will analyze the intersections between all the potential applicable regulations (pharma, agricultural, food supplements, etc) and propose an interpretative framework that addresses both the concerns or regulators, patients and industry.

16:00
Coffee Break & Networking
Coffee Break & Networking
16:30
Mesa Redonda: The future of Good Practice (GxP) for Medicinal Cannabis

The world of good practice, be it production, distribution or many others such as clinics or laboratories, forms the basis of an internationally qualified network for the pharmaceutical industry. This complex is often referred to as GxP, using different areas of “good practice”. These useful quality systems are based on the circulation of health goods around the world by defining common common denominators for product resources. If this is not possible, due to its complexity, it is even more fundamental to refer to the different stages of the process of using different plant derivatives.

This context is creating, and certainly will be, one of the challenges for kennels in the future: a need to interpret GxP in a quality and safe environment, guided by personalized, individualized and precision therapeutic options. This challenge touches both experts and regulators, science and industry, testing and their representatives, to consult some.

Primum non nocere.

17:30
Srinivasa Reddy — Impact of Cannabinoids on Health: Medical Evidences.
Srinivasa Reddy — Impact of Cannabinoids on Health: Medical Evidences.

Cannabis plants are nature’s gift. Until recently we have been unable to understand and analyze the real impact of its medicinal properties as it was formerly treated as illegal drug. Changes in legalization and government permissions have allowed medical research universities and institutes to prove the values and compatibilities of cannabis, and its derivatives, on human health issues. Srinivasa Reddy, COO/CSO of Leaf Cross Biomedical Inc., will present Impact of Cannabinoids on Health: Medical Evidences.